Jayson M I, Holland C D, Keegan A, Illingworth K, Taylor L
Rheumatic Diseases Centre, University of Manchester, Hope Hospital, Salford, UK.
Ann Rheum Dis. 1991 Jan;50(1):41-7. doi: 10.1136/ard.50.1.41.
A double blind, crossover study of fibrinolytic enhancement treatment using stanozolol has been performed in primary Raynaud's phenomenon and in systemic sclerosis. The outcome criteria included subjective evaluation, clinical examination, physiological measurements of peripheral blood flow, and fibrinolytic measurements. Nineteen patients entered and 11 completed the study of primary Raynaud's phenomenon. There was nonsignificant evidence of improvement in peripheral blood flow. Twenty four patients entered and 17 completed the study of systemic sclerosis. There was marked objective but not subjective evidence of improvement in the peripheral microcirculation during the stanozolol treatment period. There was also a nonsignificant improvement in dermal sclerosis. There were improvements in fibrinolytic activity during the stanozolol treatment period. There was no alteration in fibrinolytic reserve as measured by 1-desamino-8-D-arginine vasopressin stimulation, however. Although adverse events were common in both treatment periods, withdrawals predominantly occurred during the period of treatment with stanozolol and were principally due to anabolic problems. There does not seem to be any indication for the use of stanozolol in primary Raynaud's phenomenon. Fibrinolytic enhancement with stanozolol does appear useful in treating the microvascular features of systemic sclerosis.
已针对原发性雷诺现象和系统性硬化症开展了一项使用司坦唑醇进行纤溶增强治疗的双盲交叉研究。结局标准包括主观评估、临床检查、外周血流的生理学测量以及纤溶测量。19名患者参与了原发性雷诺现象的研究，其中11名完成了该研究。外周血流改善的证据不显著。24名患者参与了系统性硬化症的研究，其中17名完成了该研究。在司坦唑醇治疗期间，外周微循环有明显的客观改善证据，但主观改善证据不明显。皮肤硬化也有不显著的改善。在司坦唑醇治疗期间，纤溶活性有所改善。然而，通过1-去氨基-8-D-精氨酸血管加压素刺激测量的纤溶储备没有变化。尽管在两个治疗期不良事件都很常见，但撤药主要发生在司坦唑醇治疗期，主要原因是合成代谢问题。在原发性雷诺现象中似乎没有使用司坦唑醇的指征。司坦唑醇增强纤溶作用在治疗系统性硬化症的微血管特征方面似乎确实有用。
